



E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis

Supplementary Materials



Supplementary Figure 1: Forest plot shows the relation of negative E-cadherin expression with PFS of patients with ovarian cancer.



Supplementary Figure 2: Begg's and Egger's funnel plot evaluated the publication bias of the selected studies.

Supplementary Table 1: Quality assessment of studies (for cohort studies)

Studyid	Selection			Demonstration That Outcome of Interest Was Not Present at Start of Study	Comparability		Outcome		Total Points
	Representativeness of the Exposed Cohort	Selection of the Non-Exposed Cohort	Ascertainment of Exposure		Comparability of Cohorts on the Basis of the Design or Analysis	Assessment of Outcome	Was Follow-Up Long Enough for Outcomes to Occur	Adequacy of Follow Up of Cohorts	
1 Darai, E. (1996)	*	*	*	*	**	*	*	*	7*
2 Faleiro Rodrigues, C. (2004)	*	*	*	*	*	*	*	*	8*
3 Voutilainen, K. A. (2006)	*	*	*	*	*	*	*	*	8*
4 Cho, E. Y. (2006)	*	*	*	*	*	*	*	*	8*
5 Blechschmidt, K. (2008)	*	*	*	*	*	*	*	*	8*
6 Shim, H. S. (2009)	*	*	*	*	**	*	*	*	8*
7 Ho, C. M. (2010)	*	*	*	*	*	*	*	*	6*
8 Dian, D. (2011)	*	*	*	*	**	*	*	*	9*
9 Huang, K. J. (2012)	*	*	*	*	*	*	*	*	5*
10 Taskin S. (2012)	*	*	*	*	*	*	*	*	6*
11 Bacic, B. (2013)	*	*	*	*	*	*	*	*	8*
12 Huang, H. N. (2014)	*	*	*	*	**	*	*	*	9*
13 Wang, Y. (2014)	*	*	*	*	**	*	*	*	7*
14 Mise, B. P. (2015)	*	*	*	*	**	*	*	*	9*
15 Liew, P. L. (2015)	*	*	*	*	*	*	*	*	6*
16 Yu, L. (2015)	*	*	*	*	**	*	*	*	8*
17 Sundov D. (2017)	*	*	*	*	*	*	*	*	6*

Supplementary Table 2: Subgroup analysis of negative E-cadherin and prognosis of ovarian cancer patients

Stratified Analysis	No. of Study	Pools HR (95% CI)	p-value	I ²	Heterogeneity p-value
No. of Patients					
≤ 90	9	2.19 (1.49,3.22)	< 0.001	80.9%	< 0.001
> 90	8	1.41 (1.18,1.69)	< 0.001	31.4%	0.177
Years					
1996–2011	8	1.59 (1.26, 2.00)	< 0.001	50.9%	0.047
2012–2017	9	2.08 (1.42,3.07)	< 0.001	67.4%	0.002
Cut-off Value					
10%	9	1.96 (1.40,2.74)	< 0.001	80.7%	< 0.001
Others	8	1.73 (1.38,2.18)	< 0.001	35.6%	0.144
Antibody					
DAKO, Denmark	8	1.94 (1.39,2.70)	< 0.001	51.8%	0.042
Others	9	1.87 (1.36,2.57)	< 0.001	75.7%	< 0.001
Study Location					
Europe	9	2.49 (1.62,3.82)	< 0.001	74.6%	< 0.001
Asia	8	1.57 (1.15, 2.15)	0.004	68.3%	0.002